Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of orteronel versus bicalutamide in metastatic prostate cancer after castration failure
2012-002122-67Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orteronel in prostate cancer (PCa), sponsored by European Organisation for Research and Treatment of Cancer. Started Sep 2013; status: terminated.
02
Drugs
orteronel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2012-002122-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002122-67.